Ketorolac Tromethamine
syntex · TORADOL · Ketorolac (Toradol) · Ketorolac Thromethamine · KETOROLAC TROMETHAMINE SALT · Godek · Ketanov · Ketorol
식별자 및 물리적 특성
| CAS No. | 74103-07-4 |
|---|---|
| 분자식 | C19H24N2O6 |
| 평균 분자량 | 376.4 g/mol |
| 단동위원소 질량 | 376.16343649 g/mol |
| SMILES | NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O |
| InChIKey | BWHLPLXXIDYSNW-UHFFFAOYSA-N |
| PubChem CID | 84003 |
| ChEMBL | CHEMBL1201124 |
| EC No. | 620-545-3 |
| DTXSID | DTXSID0045597 |
화학 및 물리적 성질
| 극성 표면적 | 146 |
|---|---|
| 수소 결합 공여자 수 | 5 |
| 수소 결합 수용자 수 | 7 |
| 회전 가능 결합 수 | 6 |
| 무거운 원자 수 | 27 |
| 형식 전하 | 0 |
| 복잡도 | 430 |
| 용해도 | >56.5 [ug/mL] (The mean of the results at pH 7.4)H2O: 15 mg/mL -20°C.에서 최소 한 달간 안정함, 용해성 |
| Collision Cross Section | 155.6 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 녹는점 | 160-161 C |
| 저장 조건 | 2-8°C |
| 물리적 상태 | 수정 같은 |
| 색상 | 흰색에서 밝은 노란색 |
| 생물학적 소스 | synthetic (organic) |
| 용해도 | H2O: soluble 15mg/mL, clear, colorless to faintly yellow (stable at least one month at -20 °C.) |
| Merck | 14,5306 |
| 안정성 | 흡습성 |
| InChI | InChI=1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)135-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19)6-8H,1-3,5H2 |
| InChIKey | BWHLPLXXIDYSNW-UHFFFAOYSA-N |
| SMILES | C(N)(CO)(CO)CO.C(C1C=CC=CC=1)(C1=CC=C2C(C(=O)O)CCN12)=O |
화학적 성질
A carboxylic acid derivative nonsteroidal antiinflammatory agent, ketorolac tromethamine occurs as an off-white crystalline powder with a pKa of 3.54 (in water). More than 500 mg are soluble in one mL of water at room temperature. The commercially available injection is a clear, slightly yellow solution with a pH of 6.9 – 7.9. Sodium chloride is added to make the solution isotonic. Ketorolac tromethamine may also be known as RS-37619-00- 31-3; many trade names are available.
안전 및 규제
| GHS 분류 | DangerH301 (96.9%): Toxic if swallowed [Danger Acute toxicity, oral]H315 (93.8%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (93.8%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (92.2%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 64 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (96.9%)Skin Irrit. 2 (93.8%)Eye Irrit. 2 (93.8%)STOT SE 3 (92.2%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Ketorolac tromethaminevLess-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during LactationMilk levels of ketorolac are low with the usual oral dosage, but milk levels have not been measured after higher injectable dosages or with the nasal spray. Ketorolac injection is used for a short time (typically 24 hours) after cesarean section in some hospital protocols with no evidence of harm to breastfed infants. However, the ketorolac dose an infant receives in colostrum is very low because of the small volume of colostrum produced. Some evidence suggests that IV ketorolac as part of a multimodal post-cesarean section analgesia reduces percentage of mothers who fail exclusive breastfeeding compared to patient-controlled IV morphine-based analgesia. Ketorolac has strong antiplatelet activity and can cause gastrointestinal bleeding. The manufacturer indicates that ketorolac is contraindicated during breastfeeding, so an alternate drug is preferred after the first 24 to 72 hours when larger volumes of milk are produced, especially while nursing a newborn or preterm infant. |
용도
개요
Ketorolac tromethamine is a nonsteroidal antiinflammatory agent that exhibits analgesic and antipyretic activity. The compound is effective in the management of moderate to severe postoperative pain. It is, however, the first of this type of agent to be administered parenterally as an analgesic and is specifically indicated for intramuscular injection. Ketorolac represents a useful alternative to the narcotic analgesics due to its lack of abuse potential.
용도
Cyclo-oxygenase inhibitor; analgesic; anti-inflammatory.
일반 설명
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Ketorolac Tromethamine belongs to the class of non-steroidal anti-inflammatory drugs, and its mode of action involves the inhibition of the bodily synthesis of prostagladins. It exhibits anti-inflammatory, antipyretic and analgesic effects.